Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levetiracetam - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB

Drug Profile

Levetiracetam - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB

Alternative Names: E Keppra; E Keppra Dry syrup 50%; EKeppra; Keppra; Keppra XR; L-059; Levetiracetam IR; Levetiracetam XR; SIB-S1; UCB-059; UCB-22059; UCB-L059

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Developer Ache Laboratories; GlaxoSmithKline; Otsuka Pharmaceutical; UCB
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Discontinued Anxiety disorders; Neuropathic pain; Parkinsonian disorders

Most Recent Events

  • 05 Jun 2018 UCB Pharma withdraws a phase II trial in Seizures in USA (IV) (NCT00627133)
  • 30 Nov 2017 Phase-III clinical trials in Partial epilepsies (Adjunctive treatment, In children, In infants, Monotherapy) in Japan (IV) (NCT03340064)
  • 30 Nov 2017 Phase-III clinical trials in Partial epilepsies (Monotherapy, Adjunctive treatment, In infants, In children) in Japan (PO) (NCT03340064)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top